Immuron presents pipeline and financial update at Coffee Microcaps conference

Immuron Limited (ASX: IMC; NASDAQ: IMRN) had its CEO, Steven Lydeamore, present at the Coffee Microcaps Conference in Sydney on September 22, 2026, according to a Form 6-K filed with the SEC. The conference session ran from 2:30pm to 3:00pm Australian Eastern Standard Time at the State Library of NSW, Sydney.¹

In the accompanying investor presentation, the company reported global sales revenue of $7.7 million for FY26, up 6%, with Australian sales revenue of $5.8 million, up 10%, and United States sales revenue of $1.8 million, up 7% (13% in USD terms).¹ The company also disclosed a gross profit margin of 64.5%, a 0.9% decline, a net loss of $(3.8) million representing a $1.4 million improvement, and cash of $9.0 million, a $6.2 million improvement.¹

On the pipeline, Immuron said IMM-124E is eligible for an end of Phase 2 meeting with the U.S. FDA for the traveler's diarrhea indication, with a Lumanity peak U.S. sales estimate of $102 million.¹ For the second asset, the company said IMM-529 has an investigational new drug application approved by the FDA and is ready to enter Phase 2 clinical trials for Clostridioides difficile infection, with a Lumanity peak U.S. sales estimate of $400 million.¹

The company described its strategy as partnering IMM-124E and IMM-529 for development and commercialization, under a model where the licensee typically funds development, registration and commercialization costs and pays the licensor upfront fees, milestones and royalties.¹

On preclinical data for IMM-529, the company cited a prevention survival rate of about 80% without antibiotics, a treatment survival rate of about 80% comparable to vancomycin, and a relapse survival rate of about 90% versus 11-22% in controls.¹

For FY27, the company outlined plans including continued Travelan sales growth, portfolio expansion, geographic sales expansion, a partnering update for IMM-529, and cash intended to fund operations through FY27-FY28.¹